Analysts Set Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Target Price at $18.20

Shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $18.20.

A number of research firms recently weighed in on BWAY. LADENBURG THALM/SH SH increased their price objective on shares of Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a report on Thursday, August 13th. New Street Research reissued a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of Brainsway in a research report on Tuesday, September 8th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research note on Sunday, August 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $20.00 price target on shares of Brainsway in a report on Thursday.

Institutional Trading of Brainsway

Several hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its stake in Brainsway by 2.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock valued at $490,000 after buying an additional 589 shares during the period. Man Group plc lifted its stake in shares of Brainsway by 4.5% in the 4th quarter. Man Group plc now owns 18,027 shares of the company’s stock worth $343,000 after acquiring an additional 782 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Brainsway by 7.4% in the third quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock valued at $431,000 after acquiring an additional 1,964 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Brainsway in the first quarter valued at approximately $40,000. Finally, Ballast Advisors LLC acquired a new position in shares of Brainsway during the first quarter valued at approximately $55,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Stock Performance

NASDAQ BWAY opened at $13.93 on Tuesday. Brainsway has a one year low of $7.14 and a one year high of $17.40. The company has a 50-day simple moving average of $15.08 and a 200-day simple moving average of $14.75. The firm has a market capitalization of $560.13 million, a PE ratio of 31.66 and a beta of 1.25.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. The firm had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. Equities analysts forecast that Brainsway will post 0.33 earnings per share for the current year.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.